Aydin Okan, Erciyestepe Mert, Öztürk Ahmet Emin, Dinç Gülhan, Uysal Emre, Atci Muhammed Mustafa, Ertürk Kayhan, Çelik Emir
Department of Medical Oncology, University of Health Sciences, Prof. Dr. Cemil Taşcioğlu City Hospital, İstanbul, Turkey.
Department of Radiation Oncology, University of Health Sciences, Prof. Dr. Cemil Taşcioğlu City Hospital, İstanbul, Turkey.
Medicine (Baltimore). 2025 Aug 1;104(31):e43576. doi: 10.1097/MD.0000000000043576.
Kaposi sarcoma (KS) is a rare disease caused by human herpesvirus-8 (HHV-8) infection, that occurs in the elderly and more often in men. We aimed to compare the clinical and prognostic features of patients with classic and AIDS-related KS who have been followed in our clinic over the last 10 years and to present real-life data in first-line treatment. We retrospectively reviewed the medical records of 73 patients with KS, 57 with classic KS and 16 with acquired immunodeficiency syndrome (AIDS)-related KS, who were followed up at our clinic between January 2014 and December 2023. Information analyzed included demographic characteristics, clinical features, treatment modalities and prognosis of the patients. The median follow-up period was 44 months in the classic KS group and 20 months in the AIDS-related group. The median age at diagnosis of classic KS patients was 67 years and 82.5% of the patients were male. The median age at diagnosis of AIDS-related KS patients was 41 years and all patients were male. The majority of patients had an Eastern Cooperative Oncology Group performance status of 0 or 1, and comorbidities were more common in the classic KS group. The most common site of involvement in both groups was the lower extremity. 48% and 69% of patients with classic KS and AIDS-related KS, respectively, received first-line systemic chemotherapy. All patients with AIDS-related KS received antiretroviral therapy. Paclitaxel was the most preferred first-line agent in both groups. An optimal overall response rate of 78% was achieved in patients with both classic KS and AIDS-related KS. 5-year overall survival was 75% in patients with classic KS and 93% in patients with AIDS-related KS. This real-world, single-center experience provides insight into the management of patients with KS in a developing country and highlights the need to improve access to standard first-line treatment.
卡波西肉瘤（KS）是一种由人类疱疹病毒8型（HHV-8）感染引起的罕见疾病，多见于老年人，男性更为常见。我们旨在比较过去10年在我们诊所随访的经典型和艾滋病相关型KS患者的临床和预后特征，并呈现一线治疗的实际数据。我们回顾性分析了2014年1月至2023年12月在我们诊所随访的73例KS患者的病历，其中57例为经典型KS，16例为艾滋病相关型KS。分析的信息包括患者的人口统计学特征、临床特征、治疗方式和预后。经典型KS组的中位随访期为44个月，艾滋病相关型组为20个月。经典型KS患者的诊断中位年龄为67岁，82.5%的患者为男性。艾滋病相关型KS患者的诊断中位年龄为41岁，所有患者均为男性。大多数患者的东部肿瘤协作组体能状态为0或1，合并症在经典型KS组更为常见。两组最常见的受累部位均为下肢。经典型KS和艾滋病相关型KS患者分别有48%和69%接受了一线全身化疗。所有艾滋病相关型KS患者均接受了抗逆转录病毒治疗。紫杉醇是两组中最常用的一线药物。经典型KS和艾滋病相关型KS患者均实现了78%的最佳总缓解率。经典型KS患者的5年总生存率为75%，艾滋病相关型KS患者为93%。这种真实世界的单中心经验为发展中国家KS患者的管理提供了见解，并强调了改善标准一线治疗可及性的必要性。
